Roy Somak, Tremblay Martine W, Lockhart Edward, Aradhya Swaroop, Bayrak-Toydemir Pinar, Bowser Mark, DaRe Jeana, Gibson Kristin, Kennemer Michael, Krueger Christopher, Lebo Matt, Mao Rong, Nussbaum Robert, O'Fallon Brendan, Rosato Andrew, Kalman Lisa V, Funke Birgit
Cincinnati Children's Hospital, Cincinnati, Ohio.
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
J Mol Diagn. 2025 Aug 20. doi: 10.1016/j.jmoldx.2025.07.006.
Clinical implementation of whole-genome and whole-exome sequencing by next-generation sequencing (NGS) allows for comprehensive detection of genomic alterations. However, with the growing number of clinically relevant genes and variants, there is an urgent and growing need for reference materials to optimize, validate, and quality control NGS tests. This pilot study documents the paucity of physical reference materials for widely tested genes and demonstrates the utility of in silico mutagenized reference materials to supplement physical samples when developing NGS tests. We examined published, expert curated lists of clinically relevant variants for these widely tested genes and found that publicly available reference materials were available for only 29.4%. We outline the steps for generating in silico resources and used 49 curated variants to conduct a blinded proof-of-concept study with three experienced NGS laboratories. One laboratory detected all added variants, and two detected all but one. This study revealed common scenarios that could lead to false-negative results when common pathogenic variants cannot be tested during analytical validation. This work highlights the need to establish centralized knowledge bases for common, pathogenic variants, demonstrates the utility of in silico reference materials, and provides guidance for generating in silico reference materials in-house. Additional work will be needed to generate turnkey processes for novice laboratories without in-house bioinformatics expertise.
通过下一代测序(NGS)进行全基因组和全外显子组测序的临床应用能够全面检测基因组改变。然而,随着临床相关基因和变异数量的不断增加,对用于优化、验证和控制NGS检测质量的参考材料的需求日益迫切且不断增长。这项初步研究记录了广泛检测基因的实物参考材料的匮乏,并证明了在开发NGS检测时,虚拟诱变参考材料在补充实物样本方面的实用性。我们研究了这些广泛检测基因的已发表的、专家整理的临床相关变异列表,发现仅有29.4%的基因有公开可用的参考材料。我们概述了生成虚拟资源的步骤,并使用49个整理好的变异与三个经验丰富的NGS实验室进行了一项盲法概念验证研究。一个实验室检测到了所有添加的变异,另外两个实验室除一个变异外检测到了所有变异。这项研究揭示了在分析验证过程中无法检测常见致病变异时可能导致假阴性结果的常见情况。这项工作强调了为常见致病变异建立集中知识库的必要性,证明了虚拟参考材料的实用性,并为在内部生成虚拟参考材料提供了指导。对于没有内部生物信息学专业知识的新手实验室,还需要开展更多工作来生成交钥匙流程。